{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:18:35Z","timestamp":1777043915004,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81760499"],"award-info":[{"award-number":["81760499"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oncology"],"published-print":{"date-parts":[[2021,12,3]]},"abstract":"<jats:p>Purpose. To compare the difference in outcome of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVTT) between intensity-modulated radiotherapy (IMRT) concurrent with sorafenib and IMRT alone. Methods. A total of 82 patients with PVTT from 2014 to 2019 were included. Of these, 36 received IMRT concurrent with sorafenib treatment (group A), while 46 underwent IMRT alone (group B). The dose of IMRT was 40.0\u201362.5\u2009Gy\/2\u20132.5\u2009Gy\/4\u20136\u2009w, and patients received orally administered sorafenib 400\u2009mg twice a day in combination with IMRT. Overall survival (OS), progression-free survival (PFS), and median distant metastasis-free survival (DMFS) were evaluated by using LIFETEST procedure of SAS. Results. The median survival time was 11.0 months in group A versus 9.0 months in group B. The 1- and 2-year OS in group A were 44.9% and 3.8% versus 28.6% and 2.6% in group B (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>=<\/a:mo>\n                        <a:mn>0.036<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>), respectively. The median PFS was 6.0 months in group A versus 3.0 months in group B. The 1- and 2-year PFS in group A were 20.7% and 6.9% versus 2.7% and 0.0% in group B (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>=<\/c:mo>\n                        <c:mn>0.012<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>), respectively. The 1- and 2-year DMFS in group A were 38.0% and 7.9% versus 16.7% and 0.0% in group B (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>=<\/e:mo>\n                        <e:mn>0.019<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>), respectively. Multivariate analysis showed that Child\u2013Pugh classification, AFP response, and overall response were independent risk factors for OS (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). There were no significant differences in adverse events except fatigue and skin reactions between the two groups. Conclusion. Compared with IMRT alone, IMRT concurrent with sorafenib can improve the long-term efficacy of HCC patients with PVTT, without increasing adverse reactions. The patients with Child\u2013Pugh A, overall response, and AFP response obtained better OS.<\/jats:p>","DOI":"10.1155\/2021\/9943683","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T17:35:13Z","timestamp":1638552913000},"page":"1-10","source":"Crossref","is-referenced-by-count":22,"title":["Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8685-5138","authenticated-orcid":true,"given":"Munire","family":"Abulimiti","sequence":"first","affiliation":[{"name":"Department of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7326-976X","authenticated-orcid":true,"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Abdominal Radiotherapy, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-8033","authenticated-orcid":true,"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Abdominal Radiotherapy, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4364-0564","authenticated-orcid":true,"given":"Palida","family":"Apiziaji","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Abdominal Radiotherapy, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-6545","authenticated-orcid":true,"given":"Yisikandaer","family":"Abulimiti","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Abdominal Radiotherapy, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-5721","authenticated-orcid":true,"given":"Yao","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Abdominal Radiotherapy, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.01.01"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2015.05.009"},{"issue":"39","key":"4","first-page":"554","article-title":"Progress of surgery combined with radiotherapy for primary hepatocellular carcinoma","volume":"39","author":"Y. L. Wu","year":"2019","journal-title":"Chinese Journal of Radiation Medicine and Protection"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.014"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14131946"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11211"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.11.048"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01065"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-010-0314-0"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090929"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070985"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5847"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0250"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016557"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.03.010"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8400"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9826-17"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019660"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.2061"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.11.004"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i31.4360"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrt082"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0831-y"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.017"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.01.018"}],"container-title":["Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2021\/9943683.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2021\/9943683.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2021\/9943683.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T17:35:19Z","timestamp":1638552919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jo\/2021\/9943683\/"}},"subtitle":[],"editor":[{"given":"Pierfrancesco","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":29,"alternative-id":["9943683","9943683"],"URL":"https:\/\/doi.org\/10.1155\/2021\/9943683","relation":{},"ISSN":["1687-8469","1687-8450"],"issn-type":[{"value":"1687-8469","type":"electronic"},{"value":"1687-8450","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}